1,1-Dimethylethyl (2S)-2-[(methoxymethylamino)carbonyl]-5-methyl-1-pyrrolidinecarboxylate | 374929-21-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,1-Dimethylethyl (2S)-2-[(methoxymethylamino)carbonyl]-5-methyl-1-pyrrolidinecarboxylate
• 英文别名: tert-butyl (2S)-2-[methoxy(methyl)carbamoyl]-5-methylpyrrolidine-1-carboxylate
• CAS: 374929-21-2
• 化学式: C₁₃H₂₄N₂O₄
• 分子量: 272.345
• InChiKey: JRMWKUIBOQIORW-AXDSSHIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.79
• 重原子数：
  19.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  59.08
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1,1-Dimethylethyl (2S)-2-[(methoxymethylamino)carbonyl]-5-methyl-1-pyrrolidinecarboxylate 在 盐酸 、 sodium tetrahydroborate 、 正丁基锂 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 (2S,5R)-2-[(S)-(3,4-Dichloro-phenyl)-hydroxy-methyl]-5-methyl-pyrrolidine-1-carboxylic acid {4-[(2,2-dimethyl-propionylamino)-methyl]-phenyl}-amide
  参考文献：
  名称：

  Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

  摘要：

  Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00538-8
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 sodium hydroxide 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 1,1-Dimethylethyl (2S)-2-[(methoxymethylamino)carbonyl]-5-methyl-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  Discovery and initial structure–Activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists

  摘要：

  Thrombin is the most potent agonist of platelet activation, and its effects are predominantly mediated by platelet thrombin receptors. Therefore, antagonists of the thrombin receptor have potential utility for the treatment of thrombotic disorders. Screening of combinatorial libraries revealed 2 to be a potent antagonist of the thrombin receptor. Modifications of this structure produced 11k, which inhibits thrombin receptor stimulated secretion and aggregation of platelets. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00538-8